ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 177 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2018. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $6,107,000 | -0.7% | 80,000 | 0.0% | 1.55% | -2.4% |
| Q2 2018 | $6,149,000 | +50.7% | 80,000 | 0.0% | 1.59% | +36.5% |
| Q1 2018 | $4,079,000 | -2.3% | 80,000 | -11.1% | 1.17% | -12.8% |
| Q4 2017 | $4,174,000 | +68.1% | 90,000 | +157.1% | 1.34% | +2.9% |
| Q3 2016 | $2,483,000 | -21.9% | 35,000 | -46.2% | 1.30% | -38.8% |
| Q2 2016 | $3,179,000 | -54.4% | 65,000 | -40.9% | 2.12% | -51.1% |
| Q1 2016 | $6,964,000 | -43.6% | 110,000 | 0.0% | 4.34% | -15.8% |
| Q4 2015 | $12,340,000 | +16.5% | 110,000 | 0.0% | 5.16% | -1.0% |
| Q3 2015 | $10,594,000 | -5.9% | 110,000 | 0.0% | 5.21% | +16.3% |
| Q2 2015 | $11,263,000 | +64.9% | 110,000 | 0.0% | 4.48% | +41.3% |
| Q1 2015 | $6,830,000 | +46.6% | 110,000 | +3.6% | 3.17% | +34.6% |
| Q4 2014 | $4,660,000 | -99.9% | 106,200 | +24.9% | 2.36% | -37.2% |
| Q3 2014 | $4,811,000,000 | +238068.3% | 85,000 | +88.9% | 3.75% | +115.3% |
| Q2 2014 | $2,020,000 | – | 45,000 | – | 1.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |